

**ASX Announcement**

**22 September 2026**

## **Investor Presentation - Proposed Merger with Microba Life Sciences**

Genetic Signatures Limited (ASX:**GSS**) is pleased to provide the attached investor presentation regarding the proposed merger with Microba Life Sciences Limited (ASX:**MAP**). The presentation outlines the strategic rationale, transaction structure, expected benefits and indicative timetable for the proposed transaction.

The presentation should be read in conjunction with today's ASX announcement regarding the proposed merger.

This announcement has been authorised for release by the Board of Genetic Signatures Limited.

**– END –**

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us:

**Mike Aicher**  
Chair  
Genetic Signatures Limited  
[info@geneticsignatures.com](mailto:info@geneticsignatures.com)

### **About Genetic Signatures**

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.



**Genetic Signatures**

Transforming Molecular Diagnostics

# **Proposed Microba Merger Presentation**

22 September 2026

ersonal use only





Combining two complementary Australian diagnostics businesses to create a scaled, cash-backed ASX-listed group serving an expanded gastrointestinal testing pathway

## ✓ Creates a scaled ASX-listed diagnostics group

- Approximately \$30 million of combined FY26 revenue, around 149 employees, and products reaching more than 30 countries

## ✓ Complementary rather than overlapping

- GSS sells syndromic PCR to hospital and reference laboratories while Microba sells metagenomic testing to clinicians and pharma partners

## ✓ A stronger balance sheet with the transaction funded entirely in scrip

- Approximately A\$30 million of combined cash and term deposits

## ✓ Recommended by both the Genetic Signatures and Microba Boards

- Unanimously recommended, subject to a superior proposal, the Independent Expert's conclusion and finalisation and execution of the Scheme Implementation Deed (which will contain customary fiduciary carve outs and conditions precedent)

### Vision for the merged group

- To be the **ASX-listed leader in gastrointestinal and infectious disease diagnostics**
- To serve a broader customer base, from rapid first-line pathogen detection to metagenomic profiling
- To take cleared, differentiated Australian products to a **materially wider route to market**
- To reach **profitability on a single cost base**



## GSS to acquire 100% of Microba Life Sciences by scheme of arrangement, funded entirely in GSS scrip

|                      |                                                                                                                                                                                                                                          |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Structure</b>     | <ul style="list-style-type: none"><li>GSS acquires 100% of the issued shares in Microba Life Sciences (ASX: MAP) by scheme of arrangement under Part 5.1 of the Corporations Act. The merged group remains listed as ASX:GSS</li></ul>   |
| <b>Consideration</b> | <ul style="list-style-type: none"><li>0.654 new GSS shares for each Microba share. No cash consideration, no new debt and no financing condition</li></ul>                                                                               |
| <b>Implied value</b> | <ul style="list-style-type: none"><li>Merger exchange ratio determined by the prior one month VWAP of 5.48 cents per Microba share and prior one-month VWAP of 8.38 cents per Genetic Signatures share as at 18 September 2026</li></ul> |
| <b>Ownership</b>     | <ul style="list-style-type: none"><li>Approximately 469 million new GSS shares issued. Microba shareholders will hold approximately 67% and GSS shareholders will hold approximately 33% of the merged group, undiluted.</li></ul>       |
| <b>Pro forma</b>     | <ul style="list-style-type: none"><li>FY26 revenue of approximately \$30 million and combined cash and term deposits of approximately \$30 million at 30 June 2026.</li></ul>                                                            |
| <b>Board</b>         | <ul style="list-style-type: none"><li>Six directors, three nominated by GSS and three by Microba.</li></ul>                                                                                                                              |
| <b>Approvals</b>     | <ul style="list-style-type: none"><li>Microba scheme and Court approval; GSS shareholder approval under ASX Listing Rule 7.1 and all for all other purposes; Independent Expert; regulatory and customary approvals</li></ul>            |



## Four key reasons the Board considers the merger to be in the interests of GSS shareholders



### Significantly Enhanced Scale

- Approximately \$30 million of combined FY26 revenue, against \$14.8 million for each company in isolation
- Around 149 employees, manufacturing in Sydney and Brisbane, and distribution in more than 30 countries
- A larger, more liquid listed vehicle with the potential to re-rate as revenue and earnings scale



### Materially Wider Route to Market

- Microba's Sonic Healthcare and SYNLAB relationships alongside GSS' hospital and reference laboratory customers
- Each product range gains access to a customer base it does not currently serve
- A combined UK platform in the group's fastest-growing market



### Financially Attractive Combination

- Approximately \$30 million of combined cash and term deposits, funded entirely in scrip
- A minimum of \$2.5-3.0 million of annualised gross cost synergies have been identified
- A single listed cost base: one board, one audit, one listing and one corporate overhead



### Well Positioned for Future Growth

- A differentiated end-to-end gastrointestinal offering that neither company can deliver alone
- A balance sheet that is anticipated to provide a runway through to cash flow breakeven
- GSS shareholders retain their holding, their listing and three of six board seats



**Microba is an ASX-listed precision microbiome company with clinical testing in Australia and the UK, a supplements business and a live biotherapeutics pipeline**

## 1 Metagenomic Diagnostics

- Microbiome Explorer and MetaPanel clinical testing, with GI Navigator released in Q2 FY27
- FY26 group core testing volume up 78% and group core testing revenue up 92% year on year

## 2 Channels & Partners

- Distribution relationships with Sonic Healthcare, SYNLAB and Genova Diagnostics
- 43 enterprise clinic accounts signed in Australia since November 2025, with more than 175 further targets in the pipeline
- FY26 group revenues of \$14.8m

## 3 Established UK Platform

- Invivo Clinical customer base and clinician network
- UK core test sales up 92% on the prior corresponding period in Q4 FY26
- Sits alongside GSS' NHS customers in the group's fastest-growing market

## 4 Therapeutics Optionality

- MAP 315, a Phase 2-ready live biotherapeutic for ulcerative colitis
- Active partnering process; internal research and development investment remains paused



A single group spanning hospital laboratories, clinician networks and distribution in more than 30 countries

## Australia

- GSS manufacturing in Sydney; Microba head office and laboratory in Brisbane
- Hospital and reference laboratory customers alongside 43 signed enterprise clinic accounts

## United Kingdom

- GSS NHS and hospital customers; Microba's Invivo Clinical base and clinician network
- The group's fastest-growing market

## Europe

- GSS ten-year supply agreement with Hvidovre Hospital, Denmark; GSS distribution partners across Europe
- Microba SYNLAB partner-lab reach;

## USA and rest of world

- GSS direct representation and FDA 510(k) clearance for the GI parasite kit
- Microba partner-lab reach via Genova

Neither company duplicates the other's channel with each product range gaining access to a customer base it does not currently serve.

# Minimum Cost Synergies Expected from Merger

Proposed Microba Merger



Duplicated listed-company and corporate costs provide a minimum level of synergies from the deal

~\$0.9m

## Listed-entity and public-company costs

Board and non-executive fees, D&O insurance, group audit, share registry, investor relations, ASX and ASIC fees

~\$1.9m

## Duplicated corporate and G&A functions

Rationalisation of duplicated executive leadership and support, finance and company secretarial, people and culture, and project management functions across the two groups

~\$0.2m

## Infrastructure and professional services

Consolidated software licences, corporate office space outside the manufacturing site, and corporate advisory and consulting spend

\$2.5 - 3.0m

Minimum gross annualised cash synergies

4 months payback

One-off costs recovered from annualised savings

## Additional synergy opportunities remain available

Beyond the duplicated corporate functions quantified above, further opportunities may exist across laboratory and manufacturing footprint, procurement and consumables, combined sales and distribution channels, and shared quality, regulatory and R&D capability.

# Combined Company Contribution Analysis

Proposed Microba Merger



Genetic Signatures contributes the majority of the cash and net assets while Microba contributes the majority of near-term growth

| Contribution                             | Microba        | Genetic Signatures | Total  | MAP % | GSS % |
|------------------------------------------|----------------|--------------------|--------|-------|-------|
| Shares on Issue / Ownership merged group | ~469m          | ~227m              | ~696m  | 67%   | 33%   |
| Board seats                              | 3              | 3                  | 6      | 50%   | 50%   |
| Gross Cash, FY26A                        | 7.9            | 22.1               | 30.0   | 26%   | 74%   |
| Borrowing, FY26A                         | 2.7            | 0                  | 2.7    | 100%  | 0%    |
| Net assets (ex. cash), FY26A             | 16.5           | 13.6               | 30.1   | 55%   | 45%   |
| Revenue, FY26A                           | 14.8           | 14.8               | 29.6   | 50%   | 50%   |
| Continuing Product Growth (%), FY26A     | 53%            | -7%                | 46%    | 100%  | n/a   |
| Employees                                | c. 97          | c. 52              | c. 149 | 65%   | 35%   |
| Countries served                         | AU, UK, EU, US | 30+                | 30+    | n/a   | n/a   |

## Considerations for the merger

Genetic Signatures contributes roughly three quarters of the combined cash and the larger share of net assets. Microba contributes the larger share of near-term revenue growth and is expected to reach cash-flow breakeven before Genetic Signatures. The ownership split reflects a combination of the current balance sheets and the expected forward contribution of both businesses with governance balanced equally at Board level.

*Note: Financial figures in A\$ million. Market data displayed per trading data as at close of 18<sup>th</sup> September, 2026. Combined group information indicative only. Shares on Issue and Ownership demonstrated for Microba under current offer terms.*




**1** Significantly enhanced scale

**2** A materially wider route to market

**3** A more financially attractive combination that is funded through to expected cash-flow breakeven

**4** Well positioned for future growth



**Creates a scaled ASX-listed leader in gastrointestinal and infectious disease diagnostics, for the benefit of patients, laboratories, clinicians and shareholders**



| Event                                                                                       | Indicative date     |
|---------------------------------------------------------------------------------------------|---------------------|
| Despatch of the GSS Notice of Meeting                                                       | late September 2026 |
| Convene GSS shareholder meeting to approve Proposed Merger                                  | October 2026        |
| Execution of the Scheme Implementation Deed (subject to receiving GSS shareholder approval) | October 2026        |
| Lodgement of the Scheme Booklet with ASIC                                                   | mid November 2026   |
| First Court hearing                                                                         | December 2026       |
| Despatch of the Scheme Booklet to Microba shareholders                                      | December 2026       |
| Microba Scheme Meeting                                                                      | January 2027        |
| Second Court hearing                                                                        | January 2027        |
| Effective Date                                                                              | January 2027        |
| Scheme record date                                                                          | February 2027       |
| Implementation Date and issue of new GSS shares                                             | February 2027       |



## Conditions to implementation

- Receipt of any required ASX confirmations or approvals.
- GSS shareholder approval to proceed with the Proposed Merger and issue the relevant consideration securities.
- Finalisation and execution of a definitive Scheme Implementation Deed appending the form of Scheme of Arrangement and Option Scheme(s).
- Completion of the applicable independent expert process for the schemes of arrangement.
- Preparation and ASIC approval of a scheme booklet and court approval for the convening of scheme meetings of both Microba shareholders and option holders by Microba.
- Convening of the scheme meetings and approval of the proposed schemes of arrangement by the requisite majorities of both Microba shareholders and option holders.
- Court approval of the proposed scheme of arrangement.
- Satisfaction or waiver of all other required regulatory confirmations or approvals and the conditions contained in the Scheme Implementation Deed.



## Integration and synergy realisation

Estimated synergies may not be achieved in full or on the timetable assumed, and one-off costs to achieve them may exceed estimates.

## Customer and channel concentration

A substantial share of GSS revenue is driven by a small number of laboratory customers. Microba's largest shareholder, Sonic Healthcare, competes with some of those customers.

## Regulatory approvals

The Proposed Merger will be subject to obtaining all necessary regulatory and shareholder approvals that may be required, including approvals from the shareholders of both GSS and Microba

## Therapeutics funding

Microba's therapeutics pipeline, including MAP 315, is currently paused for internal research and development. Advancing it would require partnering or further funding.

## Forecast risk

The combined forecasts rest on management projections for both businesses. Residual risk remains in achieving what are, in places, ambitious financial targets.

## Funding and balance sheet

The merged group remains loss-making and carries Microba's existing debt. Further funding may be required if the combined cash burn does not reduce as assumed.

## Completion risk

The transaction is subject to several conditions. A prolonged process consumes cash and management attention whether or not it completes.

## Key person reliance

Both companies rely on specialist scientific and commercial leaders to deliver their respective products. Uncertainty through integration could see some of them leave, taking capability and customer relationships with them.



## Important Notice

This presentation has been prepared by Adelaide Equity Partners Limited t/a AE Advisors on behalf of Genetic Signatures Limited (**GSS**).

### Summary information

This presentation contains summary information about GSS and its activities current as at the date of this presentation together with information regarding the proposed acquisition of all the issued share capital in Microba Life Sciences Limited (ASX: MAP) (**Microba**) (**Proposed Merger**). The information contained in this presentation is for information purposes only.

Certain information in this presentation has been sourced from Microba, its representatives or associates, including from Microba's market announcements. Although steps have been taken to confirm the information, GSS has not been able to verify the accuracy, reliability or completeness of all such information and no representation or warranty, express or implied, is made by GSS as to its accuracy, reliability or completeness. If any such information is or proves to be inaccurate, incomplete or misleading, there is a risk that the actual financial position and performance of Microba following implementation of the Proposed Merger may be materially different to the financial position and performance expected by GSS and reflected in this presentation. There is also no assurance that the due diligence to be conducted will be conclusive and that all material issues and risks in respect of the Proposed Merger will be identified or managed appropriately.

The information in this presentation is supplied in summary form, is of a general background nature and does not purport to be complete or to provide all information that an investor should consider when making an investment decision. It should be read in conjunction with GSS's periodic and continuous disclosure announcements filed with the ASX.

This presentation is not and should not be taken to be, a prospectus, product disclosure statement or any other offering document under Australian law or any other law, and does not contain all of the information which would be required to be disclosed in such a document (and will not be lodged with ASIC or any foreign regulator).

Neither AE Advisors, any director, partner or employee of AE Advisors (**AE Persons**), nor GSS and its related bodies corporate, officers, employees, representatives, advisers and consultants (**GSS Persons**), are liable for any error or inaccuracy contained herein, whether negligently caused or otherwise, or for loss or damage suffered by a recipient of this presentation or any other person due to such error, omission or inaccuracy. In particular, any numbers, valuations and schedules contained in this presentation are preliminary and may not be relied upon.

### Financial data

All amounts are in Australian Dollars (\$) or AUD unless otherwise indicated. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All references starting with "FY" refer to the financial year ending 30 June. For example, "FY26" refers to the financial year ending 30 June 2026.

Investors should note that this presentation includes both audited and unaudited financial information for various periods. With the exception of the audited financial information, investors should note that this information has not been audited and is based on management estimates and not on financial statements prepared in accordance with applicable statutory requirements. Accordingly, investors should treat this information with appropriate caution.

Investors should also be aware that certain financial data included in this presentation including measures described as "pro forma", are "non-IFRS financial information" under ASIC Regulatory Guide 230 (Disclosing non-IFRS financial information). The non-IFRS financial measures do not have a standardised meaning prescribed by Australian International Financial Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.



## Future performance

Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding GSS's intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial conditions, including, without limitation, forecasted economic indicators and performance metric outcomes. This presentation contains words such as 'will', 'may', 'expect', 'indicative', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'probability', 'risk', 'forecast', 'likely', 'estimate', 'anticipate', 'believe', or similar words to identify forward-looking statements. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. These forward-looking statements reflect GSS's current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond the control of GSS, and have been made based upon GSS's expectations and beliefs concerning future developments and their potential effect on GSS. There can be no assurance that future developments will be in accordance with GSS's expectations. A number of important factors could cause GSS's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including but not limited to, general economic conditions in Australia and other jurisdictions in which GSS or its related bodies corporate operate; exchange rates; competition in the markets in which GSS will operate and the inherent regulatory risks in the business of GSS. Assumptions on which forward-looking statements in this presentation are based may or may not prove to be correct and there can be no assurance that actual outcomes will not differ materially from these statements. None of the AE Persons or GSS Persons, nor any other person referred to in this presentation makes any representation as to the accuracy or likelihood of fulfilment of the forward-looking statements or any of the assumptions upon which they are based. When relying on forward-looking statements to make decisions with respect to GSS, investors and others should carefully consider such factors and other uncertainties and events.

GSS is under no obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, after the date of this presentation. As such, undue reliance should not be placed on any forward-looking statement. To the maximum extent permitted by law, GSS and its related bodies corporate, officers, employees, agents and advisers and any other person referred to in this presentation:

- disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions or as a result of new information, future events or otherwise;

- do not make any representation or warranty, express or implied, as to the accuracy, reliability, fairness or completeness of such information, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and

- disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

Past performance information given in this presentation is given for illustrative purposes only and is not necessarily a guide to future performance and no representation or warranty is made by any person as to the likelihood or achievement or reasonableness of any forward-looking statements, forecast financial information or future share price performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty, or guarantee as to the past, present or the future performance of GSS.

## Not financial product advice

This presentation is for information purposes only and it is neither financial product nor investment advice (nor tax, accounting or legal advice) nor a recommendation to acquire GSS shares and has been prepared without taking into account the objectives, financial situation or needs of recipients of this presentation. It is not intended that it be relied upon as advice to investors or potential investors, who should make their own enquiries and investigations regarding an investment in GSS and in relation to all information in this presentation (including but not limited to the assumptions, uncertainties and contingencies which may affect the future operations of GSS and the value and the impact that different future outcomes may have on GSS) and before making any investment decisions, should consider the appropriateness of the information having regard to their specific investment objectives, financial situation or particular needs and should seek independent professional advice appropriate to their jurisdiction before making an investment decision.

GSS is not licensed to provide, and this presentation does not constitute the provision of, investment or financial product advice in respect of GSS's shares.



# Genetic Signatures

Transforming Molecular Diagnostics

## Contact us

P: +61 (0)2 9870 7580

E: [info@geneticsignatures.com](mailto:info@geneticsignatures.com)

## Visit us

[geneticsignatures.com](http://geneticsignatures.com)

## Follow us

